


## PHARMACEUTICAL 2021



## Sage Therapeutics Inc. Rank 3 of 409







## PHARMACEUTICAL 2021



## Sage Therapeutics Inc. Rank 3 of 409



The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 528% points. The greatest weakness of Sage Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 422%, being 777% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,122,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	67,204
Liabilities, Non-Current	19,708
Other Assets	30,121
Other Compr. Net Income	-880
Other Expenses	28,308
Other Liabilities	0
Other Net Income	9,847
Property and Equipment	6,755
Research and Development	292,714
Revenues	1,114,200
Selling, General and Administrative Expense	196,952

Output Variable	Value in 1000 USD
Assets	2,159,246
Liabilities	86,912
Expenses	517,974
Stockholders Equity	2,072,334
Net Income	606,073
Comprehensive Net Income	605,633
Economic Capital Ratio	422%